Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1508 • ACR Convergence 2024
Clinical Characteristics and Prognosis of Late-onset Systemic Lupus Erythematosus in 305 Japanese Patients
Yuko Shirota¹, Misa Oguma², Ryo Kuwata³, Yumi Tajima⁴, Yumiko Oka⁵, Miki Takeshita², Takao Kodera² and Tomonori Ishii², ¹Tohoku University Hospital / Department of Hematology and Rheumatology, Sendai, Japan, ²Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, Sendai, Japan, ³National Center for Global Health and Medicine / Division of Rheumatic Diseases, Shinjyuku, Tokyo, Japan, ⁴Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, Sendai, Miyazaki, Japan, ⁵Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, Sendai
Background/Purpose: In recent years, the number of older patients with systemic lupus erythematosus (SLE) in Japan has been increasing, with particular attention to those developing…
Abstract Number: 1525 • ACR Convergence 2024
Early versus Late Lupus Nephritis: A Meta-analysis of Observational Studies
Alexandre Matar¹ and Omer Pamuk², ¹MetroHealth, Westlake, OH, ²University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic systemic autoimmune disorder characterized by a broad range of clinical and immunological manifestations, one of which is…
Abstract Number: 1544 • ACR Convergence 2024
Comparison of Efficacy and Safety Between Belimumab and Telitacicept in the Treatment of Systemic Lupus Erythematosus
wanling wei, ling lei, Cheng Zhao, hanyou mo, zhanrui chen, leting zheng, jing wen, Fang Qin, xiaoling liao, wen zeng and fei dong, The First Affiliated Hospital of Guangxi Medical University, nanning, China (People's Republic)
Background/Purpose: B cells play an important role in the pathogenesis of systemic lupus erythematosus(SLE).Multiple biological agents with B lymphocyte as the therapeutic target have recently emerged…
Abstract Number: 1683 • ACR Convergence 2024
68Ga-FAPI PET/CT Imaging for Assessing Renal Tubulointerstitial Fibrosis in Lupus Nephritis
Shuyi Yu, Zetao Ding, Haoyu Pan, Jinyi Qian, Zhixia Yang, Xiaohan Wei, Chengde Yang and Hui Shi, Department of Rheumatology and lmmunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, China (People's Republic)
Background/Purpose: To evaluate the feasibility of using fibroblast activating protein inhibitor (FAPI) PET imaging as a molecular tracer and non-invasive tool for assessing renal tubulointerstitial…
Abstract Number: 1762 • ACR Convergence 2024
Multi-omic Analysis Defines Heterogeneous and Cell Specific Type I Interferon Signalling in Juvenile-onset SLE Patients Associated with Biomarkers of Cardiovascular Risk
Junjie Peng, Thomas McDonnell, Elizabeth Jury, Coziana Ciurtin and George Robinson, University College London, London, United Kingdom
Background/Purpose: Juvenile-onset systemic lupus erythematosus (jSLE) is an autoimmune disease characterised by chronic inflammation, multi-organ damage, and/or death. Despite their young age, jSLE patients have…
Abstract Number: 1795 • ACR Convergence 2024
Immune Complexes-Mediated Activation of Neutrophils in Systemic Lupus Erythematosus Is Dependent on RNA Recognition by TLR8
Ting Wang¹, Runa Kuley², Payton Hermanson², Gundula Min-oo³, Natasha Crellin⁴, Ching Shang³ and Christian Lood¹, ¹University of Washington, Seattle, WA, ²University of Washington, Seattle, ³Gilead Sciences, Foster City, CA, ⁴Gilead, Foster City, CA
Background/Purpose: Neutrophil activation has been implicated to contribute to the systemic lupus erythematosus (SLE) pathogenesis. However, factors and mechanisms promoting neutrophil activation in SLE have…
Abstract Number: 1844 • ACR Convergence 2024
Manufacturing of IMPT-514, a CD19/CD20 Bispecific CAR T Cell Product Candidate as a Potential Treatment of Patients with Autoimmune Diseases
Ethan BenDavid, Nathanael Joshua Bangayan, Orit Foord, Michael Weist, Melanie Munguia, Jessica Reyes and Jiajia Cui, ImmPACT Bio, West Hills, CA
Background/Purpose: Immunotherapies targeting antigens expressed on B cells are currently being explored as treatments for autoimmune disorders like antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), idiopathic…
Abstract Number: 2159 • ACR Convergence 2024
Reaching Those in Need: Understanding the Reach of a Digital Program for Lupus Self-Management Education
Katherine Carpenter¹, Melissa French², Sara Johnson³, Janet Johnson³, Ashley Holden⁴, Joy Buie¹, Melicent Miller¹ and Mary Crimmings¹, ¹Lupus Foundation of America, Washington, DC, ²Lupus Foundation of America, Alexandria, VA, ³ProChange Behavior Solutions, South Kingstown, RI, ⁴Lupus Foundation of America, Bossier City, LA

Background/Purpose: As part of a 5-year cooperative agreement with the Centers for Disease Control and Prevention, The Lupus Foundation of America (LFA) has implemented the…
Abstract Number: 2380 • ACR Convergence 2024
Characterizing SLE Patients into Type 1 and Type 2 Disease States: Insights from a Single Lupus Cohort
Angela Hu¹, Lauren Erdman², Dennisse Bonilla³, Qixuan Li³, Laura Patricia Whittall Garcia³, Dafna Gladman⁴ and Zahi Touma⁵, ¹University of British Columbia, Vancouver, BC, Canada, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³University Health Network, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: It has been proposed that SLE may be divided into Type 1 and Type 2 states. Type 1 manifestations are well captured in disease…
Abstract Number: 2398 • ACR Convergence 2024
The Relationship Between First-Trimester Maternal Serum 25-Hydroxyvitamin D and Maternal/Fetal Outcomes in Patients with Systemic Lupus Erythematosus
wen zeng¹, Yuanyuan zeng¹, Lan Zhang², Cheng Zhao¹, Fang Qin¹, Leting Zheng², Mu Huang² and ling lei¹, ¹The First Affiliated Hospital of Guangxi Medical University, nanning, China (People's Republic), ²The First Affiliated Hospital of Guangxi Medical University, nanning, Guangxi, China (People's Republic)
Background/Purpose: To identify whether serum 25-Hydroxyvitamin D (25(OH)D) level in first-trimester(before13 weeks of gestation) maternal is associated with pregnancy outcomes in patients with systemic lupus…
Abstract Number: 2416 • ACR Convergence 2024
The Impact of Active Lupus Nephritis on Work Productivity in Patients from a Latin American Lupus Cohort
Romina Nieto¹, Rosana Quintana², Diana Carolina Fernández Ávila³, Rosa Serrano Morales⁴, Guillermina Harvey⁵, Lucia Hernandez⁶, Karen Roberts⁷, Luis Catoggio⁸, Gisela Subils⁹, Carla Gobbi¹⁰, Bordón Florencia Juliana¹¹, Pablo David Ibáñez Peña¹², Leonel Ariel Berbotto¹³, María C. Bertolaccini¹⁴, Diego O. Riseni¹⁵, María De Los Ángeles Gargiulo¹⁶, Cecilia Pisoni¹⁷, Joaquín Martínez Serventi¹⁸, Emilio Buschiazzo¹⁹, Vitalina De Souza Barbosa²⁰, ODIRLEI MONTICIELO²¹, Carolina Albanez de A. Da C. Andrade²², Francinne Machado Ribeiro²³, Eloisa Bonfa²⁴, Eduardo Borba²⁴, Emília Sato²⁵, Alexis Bondi Peralta²⁶, Silvana Donoso²⁷, Gustavo Aroca Martínez²⁸, Hellen Medina²⁸, Alex Echeverri²⁹, Sebastián Molina-Rios³⁰, Manuela Rubio³¹, Rafael López³², Mario Moreno³³, Olga Lidia Vera Lastra³⁴, Mario Pérez Cristóbal³⁵, Carlos Núñez-Álvarez³⁶, luis M Amezcua Guerra³⁷, Ignacio García-Valladares³⁸, Carlos Abud Mendoza³⁹, Dionicio Galarza-Delgado⁴⁰, Marcos Vázquez⁴¹, Astrid Paats⁴², Jorge N. Cieza Calderón⁴³, Ana Mabel Quiroz Alva⁴⁴, Roberto Muñoz Louis⁴⁵, Carina Pizzarossa⁴⁶, Adriana Carlomagno⁴⁷ RV Gamboa-Cardenas⁴⁸, Graciela Alarcon⁴⁹, Urbano Sbarigia⁵⁰, Federico Zazzetti⁵¹, Ashley Orillion⁵², Guillermo Pons-Estel¹ and Bernardo Pons-Estel¹, ¹Centro Regional de Enfermedades Autoinmunes y Reumaticas. GO-CREAR, Rosario, Santa Fe, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ³Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, ⁴Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumaticas del Grupo Oroao., Rosario, Argentina, ⁵Escuela de Estadística, Facultad de Ciencias Económicas y Estadística, Universidad Nacional de Rosario, Rosario, Argentina, Rosario, Argentina, ⁶Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), ROSARIO, Santa Fe, Argentina, ⁷Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁸Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina;, Buenos Aires, Argentina, ⁹Hospital Italiano de Córdoba, Córdoba, Argentina, Córdoba, Argentina, ¹⁰Hospital Córdoba, Ciudad de Córdoba, Argentina, Córdoba, Argentina, ¹¹Hospital Privado Universitario de Córdoba, Córdoba, Argentina, ¹²Hospital HIGA San Martín, La Plata, Argentina, La Plata, Argentina, ¹³Unidad de Enfermedades Autoinmunes, Hospital Escuela Eva Perón, Granadero Baigorria, Argentina, Granadero Baigorria, Argentina, ¹⁴Hospital Padilla, Tucumán, Argentina, Tucumán, Argentina, ¹⁵Hospital General de Agudos J.M. Ramos Mejía, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹⁶Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹⁷CEMIC, Buenos Aires, Argentina, ¹⁸Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina, CABA, Argentina, ¹⁹Hospital Señor del Milagro, Salta, Argentina, Salta, Argentina, ²⁰Hospital das Clínicas, Universidade Federal de Goias, Goias, Brazil, Goiânia, Brazil, ²¹HOSPITAL DE CLINICAS DE PORTO ALEGRE, PORTO ALEGRE, Rio Grande do Sul, Brazil, ²²Universidade Federal de Pernambuco, Pernambuco, Brazil, Pernambuco, Brazil, ²³Hospital Universitario Pedro Ernesto, UERJ, Rio De Janeiro, Brazil, Rio de Janeiro, Brazil, ²⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²⁵Universidade Federal de Sao Paulo, São Paulo, SP, Brazil, ²⁶Hospital del Salvador, Santiago, Chile, ²⁷Clinical Laboratory Hospital Regional Libertador Bernardo O'Higgins, Rancagua, Chile, Rancagua, Chile, ²⁸Universidad Simón Bolivar, Barranquilla, Colombia, Barranquilla, Colombia, ²⁹Fundación Valle del Lili, Unidad de Reumatología, Colombia, Reumatología, Colombia, ³⁰Facultad de Medicina, Universidad Nacional de Colombia. Hospital Universitario Nacional, Bogotá, Colombia, ³¹Centro de Estudios de Reumatología & Dermatología SAS, Bogotá, Colombia, ³²Servicio de Reumatología. Hospital Luís Vernaza, Guayaquil, Ecuador, Guayaquil, Ecuador, ³³Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, Guayaquil, Ecuador, ³⁴División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, CDMX, Mexico, ³⁵Centro Médico Nacional Siglo XXI, CDMX, Mexico, IMMS, Mexico, ³⁶Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, CDMX, Mexico, Mexico, Mexico, ³⁷Department of Immunology, Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico, ³⁸Depto. de Inmunología y Reumatología, Hospital General de Occidente y Universidad de Guadalajara, Guadalajara, Mexico, Guadalajara, Mexico, ³⁹Hospital Central Dr. Ignacio Morones Prieto, SLP, México, SLP, Mexico, ⁴⁰UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ⁴¹Hospital de Clínicas I, Asunción, Paraguay, Asuncion del Paraguay, Paraguay, ⁴²Hospital de Clínicas I, Asunción, Paraguay, ⁴³Hospital Nacional Edgardo Rebagliatti Martins, Lima, Perú, Lima, Peru, ⁴⁴Hospital Cayetano Heredia, Lima, Perú, Lima, Peru, ⁴⁵Hospital Docente Padre Billini, Santo Domingo, República Dominicana, Santo Domingo, Dominican Republic, ⁴⁶Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, ⁴⁷Grupo de Investigación de EAIS y Reumatológicas, Montevideo, Uruguay, ⁴⁸Universidad Científica del Sur, Lima, Lima, Peru, ⁴⁹The University of Alabama at Birmingham, Birmingham, AL, ⁵⁰Johnson & Johnson Innovative Medicine, Brussels, Belgium, ⁵¹Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵²Johnson & Johnson Innovative Medicine, Spring House, PA
Background/Purpose: The Latin American Group for the Study of Lupus (GLADEL) 2.0 is an observational prevalent and incident cohort of patients with systemic lupus erythematosus…
Abstract Number: 2433 • ACR Convergence 2024
Sequential Pneumococcal Vaccination in SLE: Immunogenicity, Side Effects and Comparison with PPSV23 Vaccination
Rudrarpan Chatterjee¹, Sai Yasaswini Kommaraju², Shincy MR³ and Amita Aggarwal⁴, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow., Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ³Central research lab, Kampewgowda Institute of Medical Sciences, Bengaluru, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: SLE patients have increased risk of invasive pneumococcal disease due to immune dysregulation and drugs used in these patients. EULAR 2019 recommendation suggest sequential…
Abstract Number: 2578 • ACR Convergence 2024
Safety, Biomarker Response, and Efficacy of E6742, a Dual Antagonist of Toll-Like Receptor 7 and 8, in a First-in-Patient, Randomized, Double-Blind, Phase1/2 Study in Systemic Lupus Erythematosus
Yoshiya Tanaka¹, Atsushi Kumanogoh², Tatsuya Atsumi³, Tomonori Ishii⁴, Fumitoshi Tago⁵, Mari Aoki⁵, Shintaro Yamamuro⁵, Keisuke Sakayori⁵, Kentaro Takahashi⁵ and Shizuo Akira⁶, ¹Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ²Osaka University, Osaka, Japan, ³Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ⁴Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, sendai, Japan, ⁵Eisai Company, Ltd., Tokyo, Japan, ⁶Osaka University Immunology Frontier Research Center, Osaka, Japan
Background/Purpose: There is strong evidence for the relationship between Toll-like receptor (TLR)7/8 and systemic lupus erythematosus (SLE) pathophysiology. Dual inhibition of TLR7/8 will modulate innate…
Abstract Number: 2663 • ACR Convergence 2024
ADI-001: An Allogeneic CD20-targeted γδ CAR T Cell Therapy with Potential for Improved Tissue Homing in Autoimmune Indications
Monica Moreno, Shon Green, Kevin P. Nishimoto, Jackie Kennedy-Wilde, Taylor Barca, Melinda Au, Simona Costanzo, Gregory Vosganian, Benjamin Hsu, Francesco Galimi and Blake T. Aftab, Adicet Therapeutics, Inc., Redwood City, CA
Background/Purpose: γδ T cells serve a role in immune surveillance and their capability to traffic to tissues is fundamental to their natural biology1. They are…
Abstract Number: 0018 • ACR Convergence 2024
Preclinical Analysisof CB-010, an Allogeneic anti-CD19CAR-T Cell Therapywith a PD-1 Knockout, for the Treatment of Patients with Refractory Systemic Lupus Erythematosus (SLE)
Elizabeth Garner, George Kwong, Tristan W Fowler, Heinrich Kufeldt, Brian Kerfs, Julie Kim, Art Aviles, Lynne Alexander, Franco Davi, Chris Holland, Jean-Yves Maziere, Ashraf Garrett, Mara Bryan, Linh Chu, Sarbani Bhaduri, Michele Gerber, Elaine Alambra, Justin Skoble, Tom Kochy, Tonia Nesheiwat, Socorro Portella, Enrique Zudaire and Steven B Kanner, Caribou Biosciences, Berkeley, CA
Background/Purpose: Autologous CD19-directed CAR-T cell therapy has been shown to eradicate aberrant B cells leading to durable clinical responses in SLE patients (Müller 2024; Wang 2024). However, autologous CAR-T cell…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].